HBPCF (Helix BioPharma) Book Value per Share: $0.14 (As of Apr. 2026)


HBPCF Helix BioPharma Corp HBPCF
28 GF Score
Price $1.71
View Full Analysis

What is Helix BioPharma Book Value per Share?

Helix BioPharma HBPCF 28 Book Value per Share is $0.14 as of Apr. 2026. GuruFocus rates HBPCF with a GF Score™ of 28/100.

Helix BioPharma's book value per share for the quarter that ended in Apr. 2026 was $0.14.

During the past 3 years, the average Book Value Per Share Growth Rate was 185.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Helix BioPharma was 185.80% per year. The lowest was -35.10% per year. And the median was -9.25% per year.

Helix BioPharma's current price is $1.71. Its book value per share for the quarter that ended in Apr. 2026 was $0.14. Hence, today's PB Ratio of Helix BioPharma is 12.21.

During the past 13 years, the highest P/B Ratio of Helix BioPharma was 7.29. The lowest was 0.00. And the median was 0.00.


Helix BioPharma  (OTCPK:HBPCF) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Helix BioPharma Book Value per Share Related Terms


Helix BioPharma Book Value per Share Historical Data

* Premium members only.

The historical data trend for Helix BioPharma's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helix BioPharma Book Value per Share Chart

Helix BioPharma Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.04 0.01 -0.02 -0.00 0.15

Helix BioPharma Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 0.15 0.15 0.15 0.14

HBPCF vs VRTX, REGN, ALNY: Book Value per Share Comparison

For the Biotechnology subindustry, Helix BioPharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Helix BioPharma PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix BioPharma's PB Ratio distribution charts can be found below:

* The bar in red indicates where Helix BioPharma's PB Ratio falls into.


HBPCF
28GF Score
Helix BioPharma Corp HBPCF
Book Value per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helix BioPharma Book Value per Share Calculation

Helix BioPharma's Book Value Per Share for the fiscal year that ended in Jul. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(11.38-0.00)/74.16
=0.15

Helix BioPharma's Book Value Per Share for the quarter that ended in Apr. 2026 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(10.68-0.00)/76.38
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Frequently Asked Questions Learn more about Book Value per Share →
What does a Book Value per Share of $0.14 mean?
Helix BioPharma (HBPCF) has a Book Value per Share of $0.14 as of Apr. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Helix BioPharma and its competitors.
Is Helix BioPharma's Book Value per Share too high?
Helix BioPharma's current Book Value per Share is $0.14. Overall, Helix BioPharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's Book Value per Share compare to VRTX and REGN?
Helix BioPharma's Book Value per Share of $0.14 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Helix BioPharma and its competitors. Helix BioPharma's current Book Value per Share is $0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current Book Value per Share of $0.14. The current Book Value per Share is $0.14. Helix BioPharma's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current Book Value per Share is $0.14 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helix BioPharma Business Description

Other Exchanges HBP0:GermanyHBP:Canada
Address 40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
28GF Score

Get the complete analysis for HBPCF

Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.71
Price